• Glytec

  Led · Equity · Jun 2025

  Glytec provides an AI-based technology platform for diabetes and related conditions, centered on its flagship Glucommander cloud-based SaaS for inpatient glycemic management. Glucommander is trusted by 400+ hospitals nationwide to improve patient safety, reduce costs, and shorten lengths of stay. The company plans to expand its platform and advance the development of new technologies addressing diabetes and related comorbidities. It intends to support hospitals in complying with upcoming CMS quality measures for inpatient glycemic control. Glytec emphasizes precision insulin management and data-driven insights to help clinicians individualize care and optimize metabolic health outcomes. The company has closed a $36 million growth investment to scale R&D, expand the platform, and support rapid response to regulatory requirements. Glytec’s core product is the FDA-cleared Glucommander eGlycemic Management System, a software platform that delivers personalized, endocrinologist-level insulin dosing across the hospital-to-home continuum. The eGMS is integrated with EHRs to track blood glucose data, detect glycemic disarray, provide personalized dosing regimens, and accelerate patients into target glucose ranges. Clinical validation includes more than 90 research studies and reported reductions such as a 99.8% decrease in low blood sugar, 36–68% lower 30-day readmissions, and length-of-stay reductions up to 3.2 days. Customers report enterprise-wide utilization at or above 95% of eligible patients, annualized cost savings up to $20,000 per licensed bed, and deployment at more than 300 U.S. hospitals including AdventHealth, Novant Health and Sentara Healthcare. Glytec plans to invest in R&D around patient safety, provider workflows, and analytics, expand integrations with EHRs, mobile apps and other diabetes technologies, and grow headcount to scale its flagship product. The company is headquartered outside of Boston (Waltham, Mass.).

• HeartFlow

  Participated · Convertible Note · Mar 2025

  Heartflow develops AI technology and the Heartflow One platform to transform coronary artery disease into a screenable, diagnosable and manageable condition. The platform provides non-invasive, precision coronary care across the guideline-directed CCTA pathway and includes Roadmap™ Analysis, FFRCT Analysis and Plaque Analysis. Heartflow One is supported by the ACC/AHA Chest Pain Guideline and backed by more than 600 peer‑reviewed publications. The company has helped clinicians manage over 400,000 patients worldwide. Under CEO John Farquhar, Heartflow is investing further in R&D to advance the CCTA+Heartflow pathway as the definitive standard for non-invasive CAD diagnosis and management. HeartFlow offers HeartFlow Analysis, a non-invasive personalized cardiac test that enables physicians to make care decisions for patients with suspected coronary artery disease. The company recently received FDA clearance for new products and now provides non-invasive coronary artery anatomy (RoadMap™ analysis), physiology (HeartFlow® FFRCT), and plaque information (Plaque analysis) based on CCTA. These products together aim to give physicians a more comprehensive understanding of a patient’s CAD and to better predict heart-attack risk. Led by CEO John Farquhar and based in Mountain View, CA, HeartFlow plans to use recently raised capital to extend demand for its commercial products, support clinical evidence, and advance its comprehensive product portfolio. The company emphasized expanding its commercial reach and continuing to build clinical validation for its offerings. HeartFlow commercializes the HeartFlow FFRct Analysis, a non-invasive technology that leverages deep learning to create personalized 3D models of patients' coronary arteries and simulate blood flow. The company will use proceeds from the financing to ramp up commercial expansion, continue technology innovation and fund additional clinical studies. Its analysis has been used by clinicians at more than 80 medical institutions and for more than 15,000 patients. In the United States several commercial payers issued positive coverage decisions and CMS assigned a New Technology APC payment; NICE issued a positive guidance recommendation in the U.K. HeartFlow says the technology reduces unnecessary invasive diagnostic coronary angiography and lowers healthcare costs for hospitals. The company is positioning the HeartFlow Analysis to become a global standard of care for diagnosing coronary artery disease. Heartflow builds noninvasive diagnostic software that reconfigures CT imaging into 3D models of coronary arteries to show blood flow and pinpoint lesions. Its flagship FFR-CT software recently received FDA clearance to market. The company says studies show its modeling method outperforms CT scanning alone. Heartflow has been venture-backed since 2009 and has raised more than $200 million to date, including a $100+ million round that closed last year. Per a regulatory filing, it has raised $35.8 million of a potential $46.3 million round; calls to the company about the new funding were unanswered and the filing did not state the purpose. The firm’s leadership and origins trace to Dr. Charles Taylor and Dr. Christopher Zarins from Stanford, and it has won recognition such as the 2011 EuroPCR Innovation Award. HeartFlow develops a noninvasive fractional flow reserve/computed tomography (FFRCT) test that uses high-performance computing and CT scan data to assess blood flow in coronary arteries. Results are transmitted through a secure web interface and presented as an interactive report to help physicians make diagnostic decisions. Initial clinical tests reportedly showed significant improvements in diagnostic accuracy over other noninvasive technologies, according to the company website. The company is recruiting participants for a multicenter clinical trial to further validate the technology. HeartFlow has secured nearly $75 million to advance its FFRCT program. It faces competition from other techniques that evaluate narrowed coronary arteries, including coronary angiography, intravascular ultrasound and CT coronarography; Boston Scientific recently had a new FFR/optical coherence tomography diagnostic tool cleared in Europe. The company was formed in 2007 by a group of Stanford University professors under the name Cardiovascular Stimulation Inc. and is based in Redwood City, California.

• Monolith Brands Group

  Led · Series A · Sep 2022

  Monolith Brands is a consumer products company that builds a portfolio of omnichannel brands across focused sector verticals, initially Pet and Baby & Toddler. The company seeks to acquire established brands with differentiated products, loyal customers, sustained operating history, and existing corporate infrastructure. Monolith currently owns 11 brands and uses a data-driven omnichannel approach to diversify revenue and mitigate risk for partner brands. Founded in 2020, Monolith has offices in New York and Utah and a team of approximately 60 people based primarily in Salt Lake City. The platform offers capital, operational resources, and sector expertise to help acquired brands scale and cross-sell to overlapping customer bases. The company positions itself for long-term growth in the U.S. e-commerce sector and plans to expand into additional sectors with similar characteristics.

• Avadim Health

  Led · Debt Financing · Oct 2018

  Avadim Health describes itself as a Bionome Therapies life sciences company that develops a portfolio of advanced, safe solutions across a broad range of health and wellness areas. The company states a mission of identifying unmet needs and addressing them in novel ways. Avadim presents a strong pipeline and a family of consumer and healthcare products. Management frames the business as rapidly growing and focused on serving customers and transforming communities. The company is based in Asheville, North Carolina and emphasizes building a recognizable brand in healthcare and consumer spaces. Recent financing activity is intended to support continued execution and growth. Avadim Technologies is a Bionome Therapies life sciences company based in Asheville, NC. The company offers a portfolio of advanced, safe solutions and maintains a strong pipeline across a broad range of health and wellness areas. Its platform aims to address significant unmet health needs in hospitals and for consumers. Avadim describes itself as rapidly growing and built around the concept of serving, with a mission to change lives and transform communities. Financially, Avadim closed an equity and debt financing with gross proceeds of approximately $17 million. Management intends to use the net proceeds primarily to invest in sales and marketing to drive execution and accelerate growth.

No current team members are available.